AstraZeneca PLC vs Merck & Company, Inc. — Stock Comparison

AZN
AstraZeneca PLC
$184.74
▼ 1.40%
vs
MRK
Merck & Company, Inc.
$112.16
▲ 2.73%
Q·Score Winner
AstraZeneca PLC
AZN7.5/10vs 6.7/10

Q·Score Breakdown

7.5
Bullish
Overall
6.7
Neutral
8.5
Quality
6.2
6.4
Health
7
7
Growth
6.2
7
Valuation
7.2
8.3
Sentiment
7.1
AZN

High-quality business with 23% return on equity and 17% profit margins.

MRK

Forward P/E of 11.5× is low relative to sector peers.

Analyst Consensus

BUY
Target $223.79 (+21.1%)
10 analysts
BUY
Target $129.74 (+15.7%)
27 analysts

Fundamentals

AZN
MRK
27.9×
Trailing P/E
31.5×
23.7×
Forward P/E
11.5×
17.2%
Profit Margin
13.6%
81.5%
Gross Margin
76.6%
23.5%
ROE
12.5%
Revenue Growth
4.9%
5.3%
Earnings Growth
0.28
Beta
0.28
Price / Book
$286.4B
Market Cap
$277.0B
$132 – $213
52-Week Range
$73 – $125

Q·Score is an educational tool and is not financial advice. Data provided by Yahoo Finance. Updated on each page load. How it's calculated →